As the world leader in the diagnosis and treatment of neurologic conditions, we know the importance of laboratory testing in a patient's episode of care. Our disease-specific tests are clinically proven, cost effective, and patient care-driven. In addition to the latest testing, when you partner with us, you extend your network to include some of the world's leading neurology experts. Our neurologists are available for consultation seven days a week to provide interpretive expertise and support.

Visit us at booth #1301 at AAN 2019 to discuss how our testing can integrate with your practice.

Featured Presentations

Sunday, May 5

Characteristics of Spontaneous Spinal Cord Infarction and Proposed Diagnostic Criteria
Platform Presentation: S6: MS and CNS Inflammatory Disease: Clinical Considerations I
1:00-3:00 p.m.
Nicholas Zalewski, M.D.

The Spectrum of Inflammatory CNS Disorders Occurring During TNF-alpha Inhibitory Therapy
Platform Presentation - S11: Autoimmune CNS Inflammatory Disorders: Clinical Advances
3:30-5:30 p.m.
Amy Kunchock, M.B.B.S., M.MED.

A Population-Based Study of Idiopathic Transverse Myelitis with Aquaporin-4-IgG and Myelin-Oligodendrocyte-Glycoprotein-IgG Assessment
Platform Presentation - S11: Autoimmune CNS Inflammatory Disorders: Clinical Advances 
3:30-5:30 p.m.
Elia Sechi, M.D.

Monday, May 6

Long-term Administration of Intrathecal Mesenchymal Stem Cells in Multiple System Atrophy – A Compassionate Use Experience
Platform Presentation - S18: Autonomic Disorders
3:30-4:45 p.m.
Wolfgang Singer, M.D.

Paraneoplastic Phosphodiesterase 10A Neurological Autoimmunity Unmasked by Immune Checkpoint Inhibitor Therapy
Platform Presentation - S21 Autoimmune Neurology: Novel Diagnostic and Predictive Biomarkers and Immunopathologic Mechanisms of Disease
3:30-5:30 p.m.
Anastasia Zekeridou, M.D.

Immune Checkpoint Inhibitor Related Neurologic Adverse Events: Clinical Spectrum, Management and Outcomes
Platform Presentation: S21: Autoimmune Neurology: Novel Diagnostic and Predictive Biomarkers and Immunopathologic Mechanisms of Disease
3:30-5:30 p.m.
Divyanshu Dubey, M.B.B.S.

Myelin Oligodendrocyte Glycoprotein Autoantibody Myelitis; Clinical Characteristics, MRI Clues and Discriminators from Other Demyelinating Myelitis Etiologies
Platform Presentation: S21: Autoimmune Neurology: Novel Diagnostic and Predictive Biomarkers and Immunopathologic Mechanisms of Disease
3:30-5:30 p.m.
Divyanshu Dubey, M.B.B.S.

Tuesday, May 7

Diagnostic Pearls in Myelitis: A Case-Based Approach 
Education Course: C130
7:00-9:00 a.m.
Eoin Flanagan, M.B., B.Ch.

Kelch-Like Protein 11 Autoantibodies are a Novel Biomarker of Testicular Cancer-Associated Paraneoplastic Encephalitis
Emerging Science Session
11:45 a.m.-12:20 p.m.
Divyanshu Dubey, M.B.B.S.

Autoimmune Neurology II Advanced: Autoimmune Encephalitis at the Frontiers of Neuroscience
Education Course: C160
3:30-5:30 p.m.
Eoin Flanagan, M.B., B.Ch.

Wednesday, May 8

The Frequency of Longitudinally Extensive Transverse Myelitis in Multiple Sclerosis in the Era of Glial Biomarkers; A Population-Based Study
Poster P4.2-055 - P4: MS Epidemiology, Co-Morbidities, and Modifiable Risk Factors
11:30 a.m.-6:30 p.m.
Asnafi Solmaz, M.D.

CSF kappa Free Light Chains as a Potential Quantitative Alternative to Oligoclonal Bands in Multiple Sclerosis" 
Platform Presentation S37: MS Biomarkers 
1:00-3:00 p.m.
Ruba Saadeh, M.B.B.S.

Friday, May 10

Evolution of Autoimmune Neurology: Recent Advances in Autoimmune Neurology
Education Course: C257
3:30-4:30 p.m.
Divyanshu Dubey, M.B.B.S.


Clinical Application of a New Antibody Discovery

A novel astrocytic autoantibody, glial fibrillary acidic protein (GFAP) has recently been described by Mayo Clinic as a biomarker of a relapsing autoimmune meningoencephalomyelitis that is responsive to immunotherapies. Seropositivity distinguishes autoimmune GFAP meningoencephalomyelitis from disorders commonly considered in the differential diagnosis. This biomarker will be available in June in all of our CNS evaluations.

40%
of patients with GFAP-IgG have co-existing antibodies

1/3
GFAP-IgG is 1/3 as common as NMDA-R antibody

MAYO CLINIC RESEARCH IN SUPPORT OF GFAP-IGG

Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Novel Meningoencephalomyelitis
JAMA Neurology

Glial Fibrillary Acidic Protein Immunoglobulin G as Biomarker of Autoimmune Astrocytopathy: Analysis of 102 Patients
Annals of Neurology


New Phenotype-Specific Evaluations

Two new evaluations have been specifically developed for autoimmune myelopathy and autoimmune pediatric encephalitis. These evaluations are the first of their kind.

MAYO CLINIC RESEARCH IN SUPPORT OF AUTOIMMUNE MYELOPATHY

Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody
JAMA Neurology

Autoimmune and Paraneoplastic Myelopathies
Seminars in Neurology

Autoimmune Myelopathy Associated with Collapsin Response-Mediator Protein-5 Immunoglobulin G
Annals of Neurology

Neuromyelitis Optica IgG Predicts Relapse After Longitudinally Extensive Transverse Myelitis
Annals of Neurology

FEATURED TESTING - Available June 2019

  • Myelopathy, Autoimmune Evaluation, Spinal Fluid (Mayo ID: MAC1)
  • Myelopathy, Autoimmune Evaluation, Serum (Mayo ID: MAS1)

CNS Demyelinating Disease (AQP4-IgG & MOG-IgG)

Testing for AQP4 and MOG antibodies allows for the most comprehensive evaluation for patients recently diagnosed with demyelinating diseases and distinguishes a spectrum of demyelinating disease from multiple sclerosis.

Mayo Clinic has developed the only fluorescence-activated cell sorting (FACS) live cell-binding assay that is currently available in the U.S. for antibody detection of AQP4 and MOG. FACS is recommended by international leaders in neuroimmunology for its increased sensitivity and specificity.

A recent study also found that live cell-based methodologies had superior PPVs to the fixed cell assays, indicating that positive results in these assays are more reliable indicators of MOG autoimmune spectrum disorders.

1/3
of AQP4-IgG (-) NMO patients positive for MOG-IgG

32%
Recurrent optic neuritis patients who are positive for AQP4-IgG or MOG-IgG

1.5x
frequency that
MOG-IgG is positive compared to
AQP4-IgG

MAYO CLINIC RESEARCH IN SUPPORT OF AQP4-IGG AND MOG-IGG

AQP4 Autoantibody Assay Performance in Clinical Laboratory Service
Neurology, Neuroimmunology, & Neuroinflammation

A Comparison Study of MOG-IgG Cell-Based Assays
Neurology, Neuroimmunology, & Neuroinflammation

FEATURED TESTING

ADDITIONAL RESOURCES
Image for "Autoimmune Gliopathies and CNS Demyelinating Disease" Webinar
Autoimmune Gliopathies and CNS Demyelinating Disease Webinar

CNS Demylinating Disease Brochure


Comprehensive Testing for Genetic Disorders

Our full menu of genetic testing focuses on genes with clinical significance and focuses on providing answers for your patients, not confusing results. Our comprehensive test menu includes hereditary epilepsy, mitochondrial disorders, peripheral neuropathies, neuromuscular diseases, and several others.

FEATURED TESTING

Chromosomal Microarray
Mitochondrial Disease
Epilepsy
Neuromuscular Disease
ADDITIONAL RESOURCES
Hereditary Epilepsy Testing [A Test in Focus]
Genetic Testing for Neurologic Conditions [Webinar]

Orexin-A /Hypocretin-1

This test has major practical implications for the diagnosis of narcolepsy with cataplexy (narcolepsy type 1). It can be utilized in the diagnosis of narcolepsy type 1, and distinguishing it from narcolepsy type 2 and idiopathic hypersomnia.


Kappa Free Light Chain

The Kappa Free Light Chain, CSF test marks a new frontier in MS testing. The test is an automated and quantitative and requires only one CSF sample, simplifying lab workflows and reducing time. Furthermore, it has comparable sensitivity and specificity to oligoclonal banding, which requires CSF and serum samples as well as specialized laboratories.

  • Kappa Free Light Chain, Spinal Fluid (Mayo ID: KCSF)

Neuro-Oncology Testing

We offer a comprehensive approach to testing that focuses on the best outcomes for the patient. Our testing method combines molecular and cytogenetic analysis (in addition to a standard morphological and
histological assessment) to provide a clear picture of the diagnosis, prognosis, and treatment options. This approach maximizes the amount of information available, allowing for a tailored treatment plan.

FEATURED TESTING

ADDITIONAL RESOURCES
Neuro-Oncology
Case Studies
Neuro-Oncology Comparison Flyer
Gene Mutations and Rearrangements by Tumor Type

To learn more about how our testing can integrate with your practice, visit us at booth #1301 at AAN 2019 or fill out the form below to have a clinical specialty representative reach out about our testing.